SCHEDULE: L1 Capital Discloses 3.0% Stake in ENDRA Life Sciences
Beneficial Ownership Disclosure
L1 Capital Global Opportunities Master Fund, Ltd. has reported a 3.0% beneficial ownership stake in ENDRA Life Sciences Inc., primarily through warrants.
Summary
- L1 Capital Global Opportunities Master Fund, Ltd. beneficially owns 35,589 shares of ENDRA Life Sciences Inc. Common Stock.
- These shares represent 3.0% of the total class of securities outstanding.
- The beneficial ownership is primarily derived from 35,589 underlying warrants.
- The percentage of class is calculated based on 1,166,441 shares of Common Stock outstanding as of October 16, 2025.
- The reporting person, L1 Capital Global Opportunities Master Fund, Ltd., is organized in the Cayman Islands.
- David Feldman and Joel Arber are directors of L1 Capital Global Opportunities Master Fund, Ltd. and may be deemed to beneficially own these securities, though they disclaim beneficial ownership for other purposes.
- The securities were not acquired and are not held for the purpose of changing or influencing control of ENDRA Life Sciences Inc.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of a passive beneficial ownership stake below the 5% threshold, indicating a neutral impact on sentiment. It does not contain performance data or strategic announcements.
Future Outlook
This filing does not contain any forward-looking statements or guidance from ENDRA Life Sciences Inc. or the reporting person regarding the issuer's future performance.
Industry Context
This filing is a routine disclosure of a passive ownership stake by an investment fund in a publicly traded life sciences company. It does not provide specific insights into broader industry trends or competitive landscape beyond the ownership structure.
Stakeholder Impact
- Shareholders: The disclosure of a 3.0% passive stake by an institutional investor may provide a minor level of confidence, but is unlikely to significantly alter perceptions given its non-controlling nature.
Key Dates
| Date | Description |
|---|---|
| June 4, 2024 | Date when the 35,589 underlying Warrants were purchased. |
| February 14, 2025 | Date of a previous Schedule 13G/A filing by L1 Capital Global Opportunities Master Fund, Ltd. covering the same warrants. |
| October 16, 2025 | Date as of which 1,166,441 shares of Common Stock were outstanding, used for percentage calculation. |
| November 6, 2025 | Date of ENDRA Life Sciences Inc.'s Registration Statement on Form S-3, which provided the outstanding share count. |
| November 14, 2025 | Date of the event requiring the filing of this Amendment No. 2 to Schedule 13G. |
Keywords
ENDRA Life Sciences, L1 Capital, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.